Drug Trial Radar · NCT03297502
Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
582
Actual
Start
Jun 2016
Primary completion
Jun 2017
Study completion Jun 2017
Sponsor
- Lead sponsor
- Par Pharmaceutical, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 3, double-blind, randomized, parallel-group, placebo-controlled, multicenter study to evaluate the safety and bioequivalence of Par Pharmaceutical Inc.'s Pimecrolimus Cream, 1% and Reference Listed Elidel® (Pimecrolimus Cream, 1%). The study compares both active treatments to a placebo control in the treatment of mild to moderate atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
pimecrolimus cream 1%Drug
Elidel (pimecrolimus) cream 1%Drug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with treatment success in each treatment groupTime frame: Day 15
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.